Hanmi Pharmaceutical said Tuesday that it recorded 243.1 billion won ($217.6 million) in sales in the second quarter of this year, an 8.3 percent increase from the same period of 2017.
The company also registered 19.9 billion won in operating profit in the same period, a 7.4 percent decrease from a year ago, while posting 14.4 billion won in net profit, a 19 percent increase.
In line with its stable growth, Hanmi continued to increase its research and development funding to 48.5 billion won, a drastic 31.8 percent increase.
“Sales increased in a variety of the company’s medications, including three of its Amosartan lineups (combined hypertension medicines), Rosuzet (hyperlipidemia treatment compound drug), Gugu and Palpal (erectile dysfunction treatment) and Rovelito (anti-hypertension treatment),” the company said. “Part of royalty paid by partners was also recognized as revenue.”
Beijing Hanmi Pharmaceutical, its Chinese affiliate, recorded sales of 51.4 billion won in sales, a 3.8 percent increase from the same period of 2017.
“The company’s sales-R&D cycle, which is a structure where the company invests its revenue into R&D for new drugs, remains stable in the second quarter,” a company official said. “We will accelerate the realization of becoming a pharmaceutical powerhouse through investing in our future vision and management.”